Callan JMB Inc. Launches Subsidiary in India and Progresses to Establish Temperature-Controlled Warehouse

Callan JMB Services (India) Private Limited to offer logistics services in India, with a planned warehouse in Pune, Maharashtra for storage and distribution of pharmaceuticals at all temperature ranges

SPRING BRANCH, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has formed Callan JMB Services (India) Private Limited to offer logistics services in India. The subsidiary has a management office and will soon have an operational warehouse in Pune, Maharashtra, India for storage and distribution of pharmaceuticals at all temperature ranges, including -80^○C, needed for storing tissue samples for clinical trials.

On June 20, 2025, Callan JMB incorporated its India business subsidiary, Callan JMB Services (India) Private Limited, to distribute pharmaceutical and wellness products within India. In addition, the U.S. Callan JMB Services (India) Private Limited will also assist Indian companies in establishing onshore manufacturing plants in the U.S. The newly incorporated company already has an agreement with Walker’s Pharmaceuticals Ltd. and is working with Brihans Natural Products Ltd. to assist both companies in establishing U.S. manufacturing plants, acting as distributors of their products in the U.S.

“Our successful track record of shipping tissue samples from India to the U.S. for clinical trials demonstrated the need for dedicated operations in India to streamline the process and reduce costs,” said Wayne Williams, Founder and CEO of Callan JMB. “We bring specialized cold chain logistics expertise that enables Indian companies to efficiently navigate the complexities of establishing operations and distribution in the U.S. market.”

Callan JMB is uniquely positioned to import tissue samples for clinical trials and active pharmaceutical ingredients (APIs), in addition to wellness products made in India. These life-changing imports will help develop new pharmaceuticals and alleviate drug shortages in the U.S. Callan JMB’s extensive knowledge of pharmaceutical compliance is a key service to companies wanting to expand into the U.S. manufacturing sector, and its cold chain distribution system will reach the Indian market reliably and safely.



About Callan JMB

Callan JMB is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge on the SEC's website at: . Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, and disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Company hereafter becomes aware.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications



212.896.1254